GEP20196941B - A pharmaceutical composition for treating gastrointestinal diseases - Google Patents

A pharmaceutical composition for treating gastrointestinal diseases

Info

Publication number: GEP20196941B
Authority: GE; Georgia
Prior art keywords: pharmaceutical composition; gastrointestinal diseases; treating gastrointestinal; sucralfate; mcm
Prior art date: 2015-01-30

Application number

GEAP201614551A

Other languages

English (en)

Inventor

Pharmaceutical Co Ltd Daewoong

Original Assignee

Dae Woong Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-01-30

Filing date

2016-01-28

Publication date

2019-01-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55169799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP20196941(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-01-28 Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma

2019-01-10 Publication of GEP20196941B publication Critical patent/GEP20196941B/en

Links

208000018522 Gastrointestinal disease Diseases 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
229960004645 bismuth subcitrate Drugs 0.000 abstract 2
ZQUAVILLCXTKTF-UHFFFAOYSA-H bismuth;tripotassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[K+].[K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZQUAVILLCXTKTF-UHFFFAOYSA-H 0.000 abstract 2
229960004291 sucralfate Drugs 0.000 abstract 2
MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 abstract 2
239000002245 particle Substances 0.000 abstract 1
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 abstract 1
229960000620 ranitidine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

GEAP201614551A 2015-01-30 2016-01-28 A pharmaceutical composition for treating gastrointestinal diseases GEP20196941B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR20150015339		2015-01-30
KR1020150147513A KR101583452B1 (ko)	2015-01-30	2015-10-22	위장질환 치료용 의약 조성물

Publications (1)

Publication Number	Publication Date
GEP20196941B true GEP20196941B (en)	2019-01-10

Family

ID=55169799

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
GEAP201614551A GEP20196941B (en)	2015-01-30	2016-01-28	A pharmaceutical composition for treating gastrointestinal diseases
GEAP201814551A GEP20186941B (en)	2015-01-30	2016-01-28	A pharmaceutical composition for treating gastrointestinal diseases

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
GEAP201814551A GEP20186941B (en)	2015-01-30	2016-01-28	A pharmaceutical composition for treating gastrointestinal diseases

Country Status (19)

Country	Link
EP (1)	EP3250199A4 (fr)
JP (1)	JP6419347B2 (fr)
KR (2)	KR101583452B1 (fr)
CN (1)	CN107205947B (fr)
AR (1)	AR105413A1 (fr)
CL (1)	CL2017001680A1 (fr)
CO (1)	CO2017006222A2 (fr)
EA (1)	EA032385B9 (fr)
EC (1)	ECSP17038599A (fr)
GE (2)	GEP20196941B (fr)
MA (1)	MA41432A (fr)
MX (1)	MX375765B (fr)
MY (1)	MY195824A (fr)
PE (1)	PE20171340A1 (fr)
PH (1)	PH12017550051A1 (fr)
SA (1)	SA517382016B1 (fr)
TW (1)	TWI635859B (fr)
UA (1)	UA116517C2 (fr)
WO (1)	WO2016122226A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101988479B1 (ko)	2017-10-11	2019-09-24	(주)휴럼	리트세노라이드를 유효성분으로 하는 헬리코박터 파이로리 균주로부터 유래되는 위장질환 예방 및 치료용 약학 조성물
WO2019199134A1 (fr) *	2018-04-13	2019-10-17	주식회사 삼양바이오팜	Composition pharmaceutique comprenant du lénalidomide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3874917T2 (de) *	1987-03-09	1993-03-04	Procter & Gamble	Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
US4990610A (en) *	1988-08-25	1991-02-05	Applied Analytical Industries, Inc.	Method for preparing high potency sucralfate
EP0403048A3 (fr) *	1989-06-14	1991-01-30	Warner-Lambert Company	Un modèle de structure de système craniomandibulaire humain
KR970006083B1 (ko) *	1992-01-22	1997-04-23	주식회사 대웅제약	위장질환 치료용 의약 조성물
ATE213635T1 (de) *	1994-04-26	2002-03-15	Chugai Pharmaceutical Co Ltd	Verfahren für die herstellung schmelz-granulierte sucralfatzubereitung
JPH0879097A (ja) *	1994-09-01	1996-03-22	Matsushita Electric Ind Co Ltd	携帯無線機
KR970006083A (ko)	1995-07-06	1997-02-19	한승준	자동차용 카울부의 와이어 고정장치 취부구조
JP2001513570A (ja) *	1997-08-25	2001-09-04	ザ、プロクター、エンド、ギャンブル、カンパニー	上部胃腸管不調治療用複合製剤
WO2000078307A1 (fr) *	1999-06-21	2000-12-28	Daewoong Pharmaceutical Co., Ltd.	Preparation pharmaceutique a administration orale ayant une action therapeutique sur les troubles gastro-intestinaux, contenant de la ranitidine enrobee, du sous-citrate de bismuth et du sucralfate
JP2006076956A (ja) *	2004-09-10	2006-03-23	Taiyo Yakuhin Kogyo Kk	胃炎の治療・予防用配合剤
KR101617054B1 (ko) *	2008-07-01	2016-04-29	라이온 가부시키가이샤	고형내복제제
KR20110105223A (ko) *	2010-03-18	2011-09-26	일양약품주식회사	일라프라졸 및 수크랄페이트와 비스무스 제제의 혼합물을 함유하는 위장질환을 예방 또는 치료하기 위한 경구용 약제 조성물
KR20140072673A (ko) *	2012-12-05	2014-06-13	(주)한국파비스제약	경구용 위장질환 치료를 위한 정제

2015
- 2015-10-22 KR KR1020150147513A patent/KR101583452B1/ko active Active
- 2015-12-31 KR KR1020150190850A patent/KR20160094268A/ko not_active Withdrawn
2016
- 2016-01-27 MA MA041432A patent/MA41432A/fr unknown
- 2016-01-27 TW TW105102582A patent/TWI635859B/zh active
- 2016-01-28 GE GEAP201614551A patent/GEP20196941B/en unknown
- 2016-01-28 EA EA201791458A patent/EA032385B9/ru not_active IP Right Cessation
- 2016-01-28 MX MX2017007567A patent/MX375765B/es active IP Right Grant
- 2016-01-28 CN CN201680007680.7A patent/CN107205947B/zh active Active
- 2016-01-28 GE GEAP201814551A patent/GEP20186941B/en unknown
- 2016-01-28 UA UAA201707833A patent/UA116517C2/uk unknown
- 2016-01-28 PE PE2017001147A patent/PE20171340A1/es unknown
- 2016-01-28 MY MYPI2017702737A patent/MY195824A/en unknown
- 2016-01-28 WO PCT/KR2016/000935 patent/WO2016122226A2/fr not_active Ceased
- 2016-01-28 JP JP2017540683A patent/JP6419347B2/ja active Active
- 2016-01-28 EP EP16743704.5A patent/EP3250199A4/fr not_active Withdrawn
- 2016-01-29 AR ARP160100272A patent/AR105413A1/es not_active Application Discontinuation
2017
- 2017-06-20 EC ECIEPI201738599A patent/ECSP17038599A/es unknown
- 2017-06-23 CO CONC2017/0006222A patent/CO2017006222A2/es unknown
- 2017-06-23 CL CL2017001680A patent/CL2017001680A1/es unknown
- 2017-07-25 PH PH12017550051A patent/PH12017550051A1/en unknown
- 2017-07-29 SA SA517382016A patent/SA517382016B1/ar unknown

Also Published As

Publication number	Publication date
JP6419347B2 (ja)	2018-11-07
WO2016122226A2 (fr)	2016-08-04
EP3250199A4 (fr)	2018-08-08
MX2017007567A (es)	2017-10-19
KR20160094268A (ko)	2016-08-09
KR101583452B1 (ko)	2016-01-11
PE20171340A1 (es)	2017-09-13
ECSP17038599A (es)	2017-09-29
PH12017550051A1 (en)	2018-01-29
CN107205947B (zh)	2020-05-22
GEAP201814551A (en)	2018-08-27
KR101583452B9 (ko)	2022-05-02
TW201639559A (zh)	2016-11-16
MA41432A (fr)	2017-12-05
EA201791458A1 (ru)	2017-11-30
GEP20186941B (en)	2019-01-10
WO2016122226A3 (fr)	2016-09-15
SA517382016B1 (ar)	2021-03-18
EA032385B1 (ru)	2019-05-31
CL2017001680A1 (es)	2018-01-12
CN107205947A (zh)	2017-09-26
JP2018503672A (ja)	2018-02-08
BR112017013857A2 (pt)	2018-02-27
AR105413A1 (es)	2017-10-04
CO2017006222A2 (es)	2017-09-20
TWI635859B (zh)	2018-09-21
MX375765B (es)	2025-03-07
UA116517C2 (uk)	2018-03-26
EA032385B9 (ru)	2019-07-31
EP3250199A2 (fr)	2017-12-06
MY195824A (en)	2023-02-22

Publication	Publication Date	Title
HUE054316T2 (hu)	2021-08-30	Gyógyászati készítmény rák kezelésére
ZA201906832B (en)	2024-02-28	Novel psma-binding agents and uses thereof
ZA201905902B (en)	2021-05-26	2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
IL263497B (en)	2020-11-30	1-tetrahydropyranylcarbonyl-3,2-dihydro-h1-indole compounds for cancer treatment
EP3092254A4 (fr)	2017-09-20	Composés et compositions pour traiter des tumeurs à her2 positif
EP3303401A4 (fr)	2018-12-26	Traitement du cancer par manipulation de la flore microbienne commensale
SG11201802915WA (en)	2018-05-30	Cancer treatment composition combining anti-cd26 antibody and other anticancer agent
IL286642A (en)	2021-10-31	Preparations, devices and methods for treatment with factor vii
EP3268387A4 (fr)	2018-10-10	Compositions et méthodes pour améliorer l'efficacité de traitement du cancer
IL274008A (en)	2020-05-31	Anti-MSLN antibody and a pharmaceutical preparation containing it for the treatment of cancer
ZA201900052B (en)	2021-10-27	Pharmaceutical combinations for treating cancer
IL275525A (en)	2020-08-31	A pharmaceutical preparation for the treatment of cancer
MX379622B (es)	2025-03-11	Compuestos espirociclicos
IL261278A (en)	2018-10-31	Pharmaceutical compositions for the treatment of cancer
ZA201707024B (en)	2019-02-27	Cancer treatment composition
IL265762A (en)	2019-06-30	Dosing regimen of avolumab for cancer treatment
PL3236961T3 (pl)	2020-11-30	Kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu złośliwego
GEP20186941B (en)	2019-01-10	A pharmaceutical composition for treating gastrointestinal diseases
IL282692A (en)	2021-06-30	Compounds derived from madrasin, a preparation and their uses for the treatment of cancer
EP3398608A4 (fr)	2020-01-01	Composition pharmaceutique pour prévenir et traiter un cancer ou des métastases cancéreuses, contenant la protéine pstl1 en tant que substance active
EP3290051A4 (fr)	2018-12-05	Composition pharmaceutique permettant le traitement et/ou la prévention du cancer
ZA201803198B (en)	2022-04-28	Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of cyp17a1 and cyp19a1
EP3698799A4 (fr)	2020-11-25	Agent thérapeutique contre l'hyperphosphatémie
PT3580211T (pt)	2021-02-01	2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro
ZA201707117B (en)	2022-11-30	Antibody compositions for tumor treatment